Project cooperationUpdated on 25 January 2026
CUTIVAX
Head of Project & IP Management at Bogazici University Center for Targeted Therapy Technologies
İstanbul, Türkiye
About
CUTIVAX PLATFORM
Tumor tissue collected during surgery or biopsy.
Cells inactivated with Far-UVC turn into immunogenic “ghosts”.
Implanted subcutaneously or in a surgical lodge near lymphatic regions.
Immune cells infiltrate & trigger local and systemic immunity.
Topic
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
Type
- Consortium/Coordinator seeks Partners
Attached files
Organisation
Similar opportunities
Project cooperation
Modified Vaccinia Ankara (MVA) platform for strong T-cell immune responses
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
Angelo Raggioli
Head of Technology Development at ReiThera srl
Rome, Italy
Project cooperation
Novel "Innate" Approaches for Vaccines in Low- and Middle-Income Countries
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
Fabrizio Chiodo
Associate Professor (Italian National Research Council) at Consiglio Nazionale delle Ricerche
Palermo, Italy
Project cooperation
- Consortium/Coordinator seeks Partners
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
Daniela Ogonczyk-Makowska
R&D Project Leader at Vaxinano
Loos, France